Dataset Information


Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway.

ABSTRACT: The aggressive nature of triple negative breast cancer (TNBC) may be explained in part by the presence of breast cancer stem cells (BCSCs), a subpopulation of cells, which are involved in tumor initiation, progression, metastasis, recurrence, and therapy resistance. The signal transducer and activator of transcription 3 (STAT3) pathway participates in the development and progression of BCSCs, but its role in TNBC remains unclear. Here, we report that Ganoderma lucidum extract (GLE), a medicinal mushroom with anticancer activity, acts on BCSCs in vitro and in TNBC pre-clinical animal tumor models by downregulating the STAT3 pathway. We show that GLE significantly reduces TNBC cell viability, and down-regulates total and phosphorylated STAT3 expression. This is consistent with the reduction of OCT4, NANOG and SOX2 expression, reduction in the BCSC population by loss of the ALDH1 and CD44+/CD24- population, the deformation of mammospheres, and the strong reduction in animal tumor volume and tumor weight. Analysis of the BCSC compartment in tumors revealed that GLE decreases the STAT3 pathway and the expression of OCT4, NANOG, and SOX2 in BCSCs. These findings demonstrate that the anti-cancer activity of GLE targets BCSCs of TNBC through the downregulation of the STAT3 pathway.

SUBMITTER: Rios-Fuller TJ 

PROVIDER: S-EPMC6267592 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7412145 | BioStudies
2018-01-01 | S-EPMC6279518 | BioStudies
2018-01-01 | S-EPMC5768915 | BioStudies
1000-01-01 | S-EPMC5385639 | BioStudies
2019-01-01 | S-EPMC6909344 | BioStudies
2016-01-01 | S-EPMC4970507 | BioStudies
2012-01-01 | S-EPMC3413333 | BioStudies
2017-01-01 | S-EPMC5530137 | BioStudies
2017-01-01 | S-EPMC5337496 | BioStudies
2016-01-01 | S-EPMC5001191 | BioStudies